Synergy in the OR
Brian Bruckner, MD, is a heart and lung transplant surgeon at Houston Methodist Hospital, with clinical expertise in cardiothoracic, cardiovascular and thoracic surgery.
When Dr. Bruckner performs a lung resection, bleeding is only one of his concerns. Air leaks are one of the most common complications following lung surgery, and they can lead to prolonged hospitalization.1 Imagine trying to ﬁll a balloon with air after you have cut it—this is what Dr. Bruckner must do when he performs lung surgery, usually to remove a cancerous lesion. “When we discover an air leak, we apply Progel® Pleural Air Leak sealant to the affected area of the lung per the indications for use,” he explains. Progel® Pleural Air Leak sealant is the only FDA-approved product available for intraoperative sealing of visible air leaks greater than 2 mm during open lung resection after standard visceral pleura closure. It forms a strong, ﬂexible hydrogel that adheres to lung tissue to maintain a strong seal, then resorbs within 30 days to promote natural healing.2
Like the AristA® AH hemostat, Progel® Pleural Air Leak sealant is a biosurgery technology recently acquired by the Davol subsidiary of Bard. Both technologies are frequently used by the same clinicians—often during the same surgical procedures. In a vascular surgery procedure in the chest, for example, Dr. Bruckner uses Arista® AH hemostat as an adjunct to conventional hemostasis to help control diffuse bleeding. Since this may not be the only surgical procedure that has been performed on the patient, Dr. Bruckner may need to address lung adhesions at the same time. Removing the adhesions sometimes results in an air leak if the lung tissue or pleura is dissected.
The synergy achieved by uniting these complementary technologies in one portfolio allows Bard and Davol to bring more value to clinicians in the operating room by providing efﬁcient, proven products to treat critically ill patients.